Find clinical trials

We have selected two potential anti-Epstein-Barr virus therapies (spironolactone and famciclovir) to test in an innovative multi-stage, multi-arm trial in order to identify the best treatment for progressive MS. Treatments will be compared to dummy-treatment.

The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) when compared to another drug named sunitinib. The study will see if IDRX-42 works well and is safe for participants whose GIST has spread or cannot be surgically removed, and who have already taken the drug imatinib.

The STRIKE clinical trial at the Alfred Hospital tests whether the medication infliximab can reduce lung inflammation in people with advanced silicosis from artificial stone exposure. This study offers hope for a potential treatment for silicosis, a progressive lung disease that currently has no approved therapy.

This proposed study 817P203, is a Phase 2 double-blind, randomised, placebo-controlled, multicentre, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 in adults with focal onset seizures. The study is planned to involve approximately 258 participants aged 18 to 70 years who have focal onset seizures at multiple study sites worldwide in the United States, Europe, and Asia Pacific. The study will have two groups of participants will be randomly assigned in a 2:1 ratio to SPN-817 (3.0 to 4.0 mg twice daily [BID]) or placebo, respectively, to achieve approximately 180 participants globally completing the study. The duration of treatment with SPN-817 or placebo will be approximately 22 to 24 weeks. The Primary Objective is to evaluate the efficacy of SPN-817 as a treatment for adult participants with focal onset seizures. The Secondary Objectives are to evaluate the safety and tolerability of SPN-817 as a treatment for adult participants with focal onset seizures, and to characterize the pharmacokinetics (PK) of huperzine A after multiple dose administrations of SPN-817 (population PK analysis).

This proposed study 817P210, is a Phase 2 Extension study aiming to evaluate the efficacy, safety, and tolerability of SPN-817 in adults with focal onset seizures, who have previously completed study 817P203 (a double blind study approved by this same HREC). The study is planned to involve a minimum of 100 of the patients that participated in the parent study. Upon enrollment, the participants will undergo a blinded Dose Titration Period of 8-10 weeks, in which Study Drug will be titrated to the participant's maximum tolerated dose (MTD) based on response. The SPN-817 MTD dose will be required to between 1.0 to 4.0 mg BID. After this, the participants will enter the proper open label extension period (at their MTD dose) . The combined duration of treatment with SPN-817 will be approximately 56 weeks.

This study will use MRI and Ultrasound techniques to help track the health of joints in patients with Haemophilia A taking Efanesoctocog Alfa Prophylaxis. The study will take place over the course of 1 year and will involve up to 5 outpatient visits (plus scans). The Efanesoctocog Alfa will be taken at home via IV (patients/guardians will be trained prior).

The purpose of this study is to compare eftilagimod alfa (efti) in combination with pembrolizumab and chemotherapy versus placebo in combination with pembrolizumab and chemotherapy among adults with metastatic non-small cell lung cancer (NSCLC).